Clinical Trial Update: Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 [Phase 1]

View source ↗

Summary

Phase 1 trial of intratumorally administered STING agonist E7766 in advanced solid tumors or lymphomas has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• E7766 (STING agonist)

Snippet

Sponsor: Eisai Inc. | Conditions: Lymphoma, Advanced Solid Tumors | Phase 1 | Status: TERMINATED | Results posted: 2024-03-07